Medical Device Distribution Agreements: Regulatory Clauses, Importer Duties, and Territory Control

Why Distribution Agreements Are a Regulatory Matter

Medical device distribution agreements are not standard commercial contracts. They allocate regulatory responsibilities that carry legal obligations under frameworks like the EU MDR, FDA regulations, and national laws worldwide. A poorly drafted distribution agreement can leave the manufacturer liable for compliance failures it cannot control, or expose the distributor to enforcement actions it did not know it faced.

The regulatory burden on distributors has increased significantly. Under the EU MDR, distributors have specific obligations under Article 14 that go well beyond logistics. Under FDA regulations, the "initial distributor" (importer) has establishment registration and medical device reporting requirements. Health Canada's proposed 2025 amendments to the Medical Device Establishment Licence (MDEL) regime would further tighten importer obligations. These regulatory requirements must be reflected in the contractual relationship between manufacturer and distributor.

This guide covers the regulatory clauses, commercial terms, and negotiation strategies that medical device manufacturers need to build into distribution agreements for global markets.

Regulatory Identity: Who Is Your Distributor?

EU MDR Economic Operator Framework

Under the EU MDR, the regulatory identity of your distribution partner determines their obligations:

A single entity can hold multiple roles. A distributor that also imports devices from outside the EU is both an importer and a distributor under the MDR and must comply with the obligations of both roles (Articles 13 and 14).

FDA: Initial Distributor vs Subsequent Distributor

Under FDA regulations (21 CFR Part 807), an "initial distributor" — also called an importer — is any person who imports a device into the US and furthers the marketing of a device from the original place of manufacture to the person who makes final delivery or sale to the ultimate user.

Initial distributors must:

• Register their establishment with FDA (21 CFR 807 Subpart E)
• Submit Medical Device Reports (MDRs) for reportable adverse events within 30 calendar days
• Report malfunctions to the manufacturer within 30 days
• Maintain complaint files and distribution records

A "distributor" under FDA rules is any person other than the manufacturer or initial distributor who furthers the marketing of a device. Distributors have fewer obligations but must still report adverse events to the manufacturer.

Canada: MDEL Holders

Health Canada's proposed November 2025 amendments to the Medical Devices Regulations would require all MDEL holders importing Class II, III, or IV devices to establish, implement, and maintain documented procedures for handling, storing, delivering, installing, servicing, and taking corrective action. The amendments would also remove certain exemptions for importers who source directly from manufacturers, tightening the net on distribution-level compliance.

Mandatory Regulatory Clauses

1. Regulatory Role and Responsibility Allocation

The agreement must explicitly define the regulatory role(s) of the distributor in each territory:

• Which MDR articles apply (Article 13 importer, Article 14 distributor, or both)
• FDA registration requirements (initial distributor obligations)
• National registration requirements (e.g., Health Canada MDEL, TGA sponsor, SFDA authorized representative)
• Who holds the local registration or listing and what happens upon termination

The agreement should specify who is responsible for maintaining regulatory registrations in each market and include a mechanism for transferring or withdrawing those registrations when the relationship ends.

2. Post-Market Surveillance and Vigilance Obligations

Drafting PMS and vigilance obligations into the distribution agreement is critical because the manufacturer depends on the distributor for field intelligence. Under the EU MDR, the distributor must:

• Forward complaints to the manufacturer and, where applicable, the authorized representative and importer immediately
• Inform the manufacturer of any identified non-conformity
• Cooperate with manufacturers and competent authorities on corrective actions
• Provide documentation and information to competent authorities upon request

The contract should specify:

• Complaint handling timelines — maximum number of days for the distributor to forward a complaint to the manufacturer (typically 5–10 business days)
• Serious incident escalation — immediate notification for events involving death, serious injury, or serious public health threat
• Adverse event reporting — who reports to which authority and in what timeframe
• Recall cooperation — the distributor's obligations to support field safety corrective actions
• Data sharing — what complaint and vigilance data the distributor must provide, in what format, and how often
• Communication control — the manufacturer should retain control of all communications with regulatory authorities to prevent misinformation that can be difficult or impossible to rectify; the distributor should be required to route all regulatory correspondence through the manufacturer before responding

3. Labeling and Product Integrity Provisions

The distributor must not modify the device, its labeling, or its packaging in ways that affect compliance with the Essential Principles or the conditions of the market authorization. Under the EU MDR, distributors who re-label or re-package devices may become the legal manufacturer, with all the obligations that entails.

The agreement should include:

• Prohibition on modifying product labeling without written manufacturer consent
• Requirements for maintaining storage and transport conditions specified by the manufacturer
• Temperature monitoring and cold chain management for applicable devices
• Traceability requirements, including UDI scanning and EUDAMED registration
• Handling of expired, damaged, or recalled products

4. Audit and Inspection Access

Regulatory authorities may audit or inspect the distributor's facilities and records. The agreement should include:

• The distributor's obligation to cooperate with regulatory inspections
• The manufacturer's right to audit the distributor's quality system, complaint handling, and record-keeping
• Frequency of audits (typically annual for high-risk devices)
• Notification requirements when a regulatory authority contacts or visits the distributor
• Access to distribution records for traceability and recall purposes

5. Data Protection and Confidential Information

Distribution agreements typically involve sharing proprietary information, including technical documentation, product specifications, and customer data. The agreement must address:

• Compliance with GDPR in the EU, PIPEDA in Canada, and other applicable data protection laws
• Restrictions on the distributor's use of manufacturer's proprietary information
• Handling of patient data if the distributor is involved in complaint handling or adverse event reporting
• Cybersecurity requirements for any shared systems or databases
• Return or destruction of confidential information upon termination

Commercial Terms That Affect Regulatory Compliance

Exclusivity and Territory Control

Territory exclusivity is the most commercially significant — and most often poorly defined — clause in distribution agreements. For medical device manufacturers, the territory must align with regulatory registrations:

• Define territory precisely by listing specific countries or regulatory jurisdictions, not vague regions
• Align territory with regulatory registrations — if the distributor is registered with a specific national authority, the territory should correspond
• Reserve manufacturer's rights for government tenders, direct institutional sales, or online channels
• Consider regulatory fragmentation — a single EU-wide exclusive territory may be inefficient if the distributor lacks regulatory capability in every member state

Exclusivity should be contingent on performance metrics:

• Minimum annual sales volumes or revenue targets
• Market coverage requirements (number of accounts, hospital systems, or regions)
• Regulatory compliance scorecards (timely complaint reporting, audit results, registration maintenance)
• Stock and inventory requirements to prevent supply disruptions

Product Scope and Change Management

The agreement must specify which products are covered and how changes are handled:

• Which product families, SKUs, or model numbers are included
• How new product launches are added to the agreement
• Procedures for product discontinuation or end-of-life
• Change notification requirements — the distributor must inform the manufacturer of any change that could affect the device's conformity
• Minimum purchase commitments and order lead times

Pricing, Payment, and Reimbursement Support

Distribution pricing in medical devices is complicated by reimbursement systems:

• Transfer pricing to the distributor
• Whether the distributor is responsible for reimbursement coding and coverage
• Price adjustment mechanisms for tariff changes, currency fluctuations, or regulatory fee increases
• Responsibilities for health technology assessment (HTA) submissions
• Transparency reporting obligations (e.g., Sunshine Act in the US, EFPIA transfer of value reporting in Europe)

Regulatory Compliance by Jurisdiction

European Union

Under the EU MDR, the key provisions to include:

• EUDAMED registration: Who registers the device and economic operators
• Vigilance obligations: The distributor must cooperate with the manufacturer on Periodic Safety Update Reports (PSURs), Post-Market Surveillance (PMS) plans, and Post-Market Clinical Follow-up (PMCF) activities
• Product liability: The EU Product Liability Directive (revised 2024) extends liability to distributors and imposes disclosure obligations. The agreement should allocate liability and insurance requirements
• Data sharing: The distributor must maintain distribution records for the period required by the MDR and make them available to competent authorities

United States

FDA-specific provisions to include:

• Establishment registration: Whether the distributor must register as an initial distributor
• MDR reporting: Who submits Medical Device Reports and within what timeframe
• UDI compliance: The distributor's role in UDI record-keeping
• FTC advertising compliance: The distributor must not make promotional claims inconsistent with the FDA-cleared or approved labeling
• State licensing requirements: Many US states require wholesale distributor licenses

Canada

With the proposed MDEL amendments, consider:

• MDEL compliance: The distributor's obligation to maintain an active MDEL
• Import procedures: Documentation requirements for customs clearance
• Bilingual labeling: Requirements for English and French labeling in Quebec and at the federal level
• Provincial procurement: Different provinces have different procurement and reimbursement systems

Middle East and Asia-Pacific

Many markets in these regions have specific local requirements:

• Local authorized representative / sponsor requirements (e.g., Saudi SFDA MDMA authorized representative, UAE EDE local representative, Singapore HSA registrant)
• Arabic labeling requirements in Saudi Arabia, UAE, and other GCC countries
• Certificate of Free Sale (CFS) or Certificate of Good Manufacturing Practice (CGMP) from the country of origin
• Local product registration that must be maintained even after a distributor change
• Import licensing that may be held by the distributor and transferable only with regulatory authority approval

Sponsor and Registration Transfer Provisions

One of the most contentious issues in medical device distribution agreements is what happens to local registrations when the relationship ends. This is particularly important in markets like:

• Australia (TGA): The sponsor holds the Australian Register of Therapeutic Goods (ARTG) entry. Transferring sponsorship requires a formal process with the TGA
• Saudi Arabia (SFDA): The Authorized Representative (AR) is linked to the MDMA listing. SFDA has published specific procedures for AR transfers
• Brazil (ANVISA): The Brazil Registration Holder (BRH) holds the registration. Transferring requires a formal petition to ANVISA
• Japan (PMDA): The Marketing Authorization Holder (MAH) holds the Shonin approval. Transfer is a regulatory process
• New Zealand (Medsafe): The Sponsor holds the WAND listing. WAND notifications cannot be reassigned — the current sponsor must make entries obsolete and the new sponsor must re-notify

The agreement should include:

• A contractual obligation on the distributor to cooperate in transferring registrations
• Specific timelines for completing transfers (typically 60–180 days)
• Provisions for who pays transfer fees and legal costs
• Interim supply arrangements during the transfer period
• Consequences for refusal to cooperate (injunctive relief, liquidated damages)

Termination and Transition Provisions

Termination clauses in medical device distribution agreements must address both commercial and regulatory transition:

Regulatory Transition Checklist

1. Notification to regulators: Inform the relevant authority of the change in distributor/representation
2. Registration transfer or withdrawal: Transfer local registrations or, if not possible, withdraw and re-register
3. Inventory disposition: What happens to unsold inventory — return to manufacturer, sell-through period, or destruction
4. Ongoing vigilance obligations: Who handles complaints and adverse events for devices already in the market
5. Recall responsibility: Who manages any recalls initiated during or after the transition period
6. Customer transition: Notification to hospitals, clinics, and other customers of the change in distribution
7. Confidential information: Return or destruction of technical files, product specifications, and customer data

Post-Termination Non-Compete and Non-Solicitation

In the EU, non-compete clauses must comply with competition law. Under the Vertical Block Exemption Regulation (VBER, Regulation 2022/720), non-compete obligations during the agreement are generally exempt from the Article 101 TFEU prohibition if they do not exceed five years, but post-termination non-competes are only allowed if they are:

• Indispensable to protect know-how transferred by the supplier to the buyer
• Limited to the contracted products and facility
• Proportionate in duration and scope to the know-how being protected

Common Mistakes in Medical Device Distribution Agreements

1. Treating It Like a Generic Commercial Contract

Medical device distribution agreements must account for regulatory obligations that generic contracts ignore. A standard distribution template will miss PMS obligations, adverse event reporting timelines, regulatory audit access, and registration transfer mechanisms.

2. Granting Territory-Wide Exclusivity Without Performance Conditions

Exclusivity without measurable performance targets leaves the manufacturer locked into a relationship where the distributor underperforms but controls the territory. Always tie exclusivity to specific, auditable metrics with clear remedies for underperformance.

3. Ignoring the Regulatory Identity of the Distributor

The distributor's regulatory role determines their legal obligations. If the agreement describes the partner as a "distributor" but they also import the device, they must comply with importer obligations — and the agreement should reflect this.

4. No Plan for Regulatory Transition Upon Termination

Many agreements have robust termination clauses for commercial matters but are silent on regulatory transition. The result is costly disputes over who controls local registrations, who pays transfer costs, and who handles ongoing vigilance obligations.

5. Inadequate Data and Complaint Handling Provisions

The manufacturer's PMS system depends on receiving timely complaint data from the field. If the agreement does not specify timelines, formats, and escalation procedures, the manufacturer cannot fulfill its regulatory obligations.

Checklist: Key Clauses for Medical Device Distribution Agreements

Practical Recommendations

1. Start with regulatory requirements, not commercial terms. Map the regulatory obligations in each target market first, then build the commercial terms around them.

2. Use separate agreements for separate roles. If the distributor is also the authorized representative and importer, consider whether these roles should be in separate agreements with different termination provisions.

3. Build in regulatory change mechanisms. Regulatory frameworks evolve — the EU MDR is still being implemented, FDA QMSR takes effect in 2026, and many countries are updating their medical device regulations. The agreement should have a mechanism for adapting to regulatory changes without full renegotiation.

4. Conduct due diligence on the distributor's regulatory capability. Can they actually fulfill the obligations you're contracting them for? Do they have a quality management system? Experience with adverse event reporting? A track record of passing regulatory audits?

5. Get regulatory counsel involved early. Distribution agreements for medical devices should be reviewed by regulatory affairs professionals, not just commercial lawyers. The regulatory clauses affect product liability exposure, market access continuity, and compliance risk.

6. Plan corrective action scenarios upfront. Think through possible corrective actions — recalls, replacements, device modifications, software updates, IFU changes — and include distributor obligations to support each scenario. Regulatory surveys by Swissmedic and the Dutch IGJ found that device companies largely fail to meet PMS expectations, often because distribution agreements do not obligate distributors to cooperate on corrective actions.